125 related articles for article (PubMed ID: 35777022)
41. Biomarkers in the prediction of contrast media induced nephropathy - the BITCOIN study.
Seibert FS; Heringhaus A; Pagonas N; Rudolf H; Rohn B; Bauer F; Timmesfeld N; Trappe HJ; Babel N; Westhoff TH
PLoS One; 2020; 15(7):e0234921. PubMed ID: 32673348
[TBL] [Abstract][Full Text] [Related]
42. Improving the diagnosis of high grade and stage bladder cancer by detecting increased urinary calprotectin expression in tumor tissue and tumor-associated inflammatory response.
Sahin Y; Yucetas U; Ates HA; Erkan E; Yucetas E; Temiz MZ; Toktas MG; Kadihasanoglu M; Topkaya BC
Investig Clin Urol; 2019 Sep; 60(5):343-350. PubMed ID: 31501796
[TBL] [Abstract][Full Text] [Related]
43. Contrast medium-induced nephrotoxicity risk assessment in adult inpatients: a comparison of serum creatinine level- and estimated glomerular filtration rate-based screening methods.
Davenport MS; Khalatbari S; Cohan RH; Ellis JH
Radiology; 2013 Oct; 269(1):92-100. PubMed ID: 23579047
[TBL] [Abstract][Full Text] [Related]
44. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
[TBL] [Abstract][Full Text] [Related]
45. Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy.
George B; Joy MS; Aleksunes LM
Exp Biol Med (Maywood); 2018 Feb; 243(3):272-282. PubMed ID: 29231123
[TBL] [Abstract][Full Text] [Related]
46. Could "calprotectin" and "endocan" serve as "Troponin of Nephrologists"?
Azimi A
Med Hypotheses; 2017 Feb; 99():29-34. PubMed ID: 28110693
[TBL] [Abstract][Full Text] [Related]
47. Anticancer drug-induced kidney disorders.
Kintzel PE
Drug Saf; 2001 Jan; 24(1):19-38. PubMed ID: 11219485
[TBL] [Abstract][Full Text] [Related]
48. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
[TBL] [Abstract][Full Text] [Related]
49. Renal function impairment in cervical cancer patients treated with cisplatin-based chemoradiation: A review of medical records in a Zimbabwean outpatient department.
Manyau PMC; Mabeka M; Mudzviti T; Kadzatsa W; Nyamhunga A
PLoS One; 2021; 16(2):e0245383. PubMed ID: 33626044
[TBL] [Abstract][Full Text] [Related]
50. Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy.
Klöckl MC; Kasparek AK; Riedl JM; Moik F; Mollnar S; Stotz M; Szkandera J; Terbuch A; Gerger A; Niedrist T; Pichler M; Bauernhofer T; Schilcher G; Zitta S; Rosenkranz AR; Friedl C; Stöger H; Posch F
Sci Rep; 2020 Jul; 10(1):11219. PubMed ID: 32641710
[TBL] [Abstract][Full Text] [Related]
51. Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder.
Ebbing J; Mathia S; Seibert FS; Pagonas N; Bauer F; Erber B; Günzel K; Kilic E; Kempkensteffen C; Miller K; Bachmann A; Rosenberger C; Zidek W; Westhoff TH
World J Urol; 2014 Dec; 32(6):1485-92. PubMed ID: 24378824
[TBL] [Abstract][Full Text] [Related]
52. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
[TBL] [Abstract][Full Text] [Related]
53. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
54. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity.
Umeki S; Tsukiyama K; Okimoto N; Soejima R
Am J Med Sci; 1989 Oct; 298(4):221-6. PubMed ID: 2552802
[TBL] [Abstract][Full Text] [Related]
55. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
Hotta K; Takigawa N; Hisamoto-Sato A; Ichihara E; Kudo K; Uchida K; Yanase-Nakamura K; Tanaka H; Kato Y; Tabata M; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2013 Nov; 43(11):1115-23. PubMed ID: 24082005
[TBL] [Abstract][Full Text] [Related]
56. Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Lavolé A; Danel S; Baudrin L; Gounant V; Ruppert AM; Epaud C; Belmont L; Rosencher L; Cadranel J; Milleron B
Bull Cancer; 2012 Apr; 99(4):E43-8. PubMed ID: 22450449
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.
Ibrahim ME; Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant CL; Bowles DW; George B; Wen X; Buckley B; Aleksunes L; Joy MS
Eur J Clin Pharmacol; 2019 Jan; 75(1):51-57. PubMed ID: 30220072
[TBL] [Abstract][Full Text] [Related]
58. Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.
Dahal A; Bellows BK; Sonpavde G; Tantravahi SK; Choueiri TK; Galsky MD; Agarwal N
Am J Clin Oncol; 2016 Oct; 39(5):497-506. PubMed ID: 24824144
[TBL] [Abstract][Full Text] [Related]
59. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
[TBL] [Abstract][Full Text] [Related]
60. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
